. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Leuk Lymphoma. 2020 Dec 28;62(5):1187–1194. doi: 10.1080/10428194.2020.1861270

Table 3.

Toxicity summary for treatment-related toxicities^*

Event		All Grades N (%)	Grades 3-4 N (%)
Cardiac	Cardiac disorders - other, specify	10 (26)	1 (3)
Cardiac	Prolonged QTc	20 (5)	5 (13)
Gastrointestinal	Anorexia	12 (32)	0 (0)
	Diarrhea	15 (39)	3 (8)
	Nausea	26 (68)	1 (3)
	Vomiting	18 (47)	0 (0)
General	Fatigue/malaise	23 (61)	3 (8)
General	Infusion-related reaction	9 (24)	0 (0)
Hematologic	Platelet count decreased	9 (24)	9 (24)
Hematologic	White blood cell decreased	11 (29)	9 (24)
Laboratory	Increased AST/ALT	9 (24)	2 (5)
Laboratory	Alkaline phosphatase increased	13 (34)	1 (3)
Neurologic	Dysgeusia	12 (32)	0 (0)
	Paresthesia	10 (26)	0 (0)
	Peripheral sensory neuropathy	11 (29)	2 (5)

Includes toxicities with incidence greater than 20%